Metastatic Colorectal Cancer MedDRA version: 21.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Sponsors
Bristol-Myers Squibb International Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Histologically confirmed previously treated CRC with adenocarcinoma histology with metastatic or recurrent unresectable disease at study entry. - Participants must have: a)progressed during or within approximately 3 months following the last administration of approved standard therapies (at least 1, but not more than 4 prior lines of therapies), which must include a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF therapy, and anti-EGFR therapy (if KRAS wild-type), if approved in the respective country, or; b)been intolerant to prior systemic chemotherapy regimens if there is documented evidence of clinically significant intolerance despite adequate supportive measures. - Participants must have sufficient tumor tissue & evaluable PD-L1 expression to meet the study requirements. Participants with indeterminate PD-L1 results will be stratified with those participants assessed to be PD-L1 negative by CPS (see next slide for details). - Participants must have historically or locally confirmed tumor MSS/pMMR status to enroll in this study. - KRAS mutation status must be documented based on available historical or local testing results as part of medical history prior to study enrollment. - Participants must have measurable disease per RECIST v1.1. Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 420 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 280
Exclusion criteria
Exclusion criteria: - Prior treatment with either an immunotherapy (anti-LAG-3, anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) or with regorafenib or with TAS-102. - Untreated CNS metastases. Participants are eligible if CNS metastases have been treated and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) - Participants with history of refractory hypertension not controlled with anti-hypertensive therapy, myocarditis (regardless of etiology), uncontrolled arrhythmias, acute coronary syndrome within 6 months prior to dosing, Class II congestive heart failure (as per the New York Heart Association Functional Classification), interstitial lung disease/pneumonitis or an active, known or suspected autoimmune disease. - In the case of prior SARS-CoV-2 infection, acute symptoms must have completely resolved and based on investigator assessment in consultation with the clinical trial physician, there are no sequelae that would place the participant at a higher risk of receiving investigational treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the efficacy of the relatlimab-nivolumab FDC to investigator’s choice standard of care therapy (regorafenib or TAS-102) in participants with late-line metastatic colorectal cancer, including all randomized participants and randomized participants with PD-L1 CPS = 1, respectively;Secondary Objective: - To compare the antitumor activity based on ORR by BICR of the relatlimab-nivolumab FDC to investigator’s choice standard of care therapy (regorafenib or TAS-102) in participants with late-line metastatic colorectal cancer, including all randomized participants and randomized participants with PD-L1 CPS =1 - To compare the antitumor efficacy based on PFS by BICR of the relatlimab-nivolumab FDC to investigator’s choice standard of care therapy (regorafenib or TAS-102) in participants with late-line metastatic colorectal cancer, including all randomized participants and randomized participants with PD-L1 CPS = 1 - To compare deterioration free survival (DeFS) of the relatlimab + nivolumab FDC to investigator’s choice standard of care therapy (regorafenib or TAS- 102) in participants with late-line metastatic colorectal cancer, including all randomized participants and randomized participants with PD-L1 CPS = 1;Primary end point(s): - Overall Survival (OS) in randomized participants with PD-L1 CPS (combined positive score;) = 1 - OS in all randomized participants ;Timepoint(s) of evaluation of this end point: Until death, up to 5 years after last Participant randomized | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1/ ORR (objective response rate) by BICR (blinded independent central review) per RECIST v1.1 in randomized participants with PD-L1 CPS = 1 and all randomized participants, respectively 2/ PFS (progression-free survival) by BICR per RECIST v1.1 in randomized participants with PD-L1 CPS= 1 and all randomized participants, respectively 3/ DoR (duration of response;) by BICR per RECIST v1.1 in responders with PD-L1 CPS = 1 and all responders, respectively 4/ Rate of AEs (adverse events), SAEs (serious adverse events), select AEs and IMAEs (immune-mediated adverse events), AEs leading to discontinuation and abnormalities in specific clinical laboratory assessments 5/ Deterioration free survival-quality of life (DeFS-QoL), which is defined as time until definitive deterioration in the EORTC QLQ-C30 global health status/QoL scale score or death, whichever is earlier in randomized participants with PD-L1 CPS = 1 and all randomized participants, respectively 6/ Deterioration free survival-physical function (DeFS-PF), which is defined as time until definitive deterioration in the EORTC QLQ-C30 physical function scale score or death, whichever is earlier in randomized participants with PD-L1 CPS = 1 and all randomized participants, Respectively;Timepoint(s) of evaluation of this end point: 1, 2, 3: Tumor assessments should continue until disease progression or death or withdrawal of consent, whichever is earlier, up to 5 years after last participant randomized 4/ up to 5 years after last participant was randomized 5, 6: Until death, up to 5 years after last participant randomized | — |
Countries
Argentina, Australia, Austria, Belgium, Canada, Chile, China, Czechia, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Contacts
Public ContactGSM-CT
Bristol-Myers Squibb International Corporation
Outcome results
None listed